TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00740558

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chiropractic adjustment
Description: Lumbar roll according to the Diversified technique of chiropractic adjusting

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Traditional chiropractic adjustment
Description: Lumbar roll according to the Diversified technique of chiropractic adjusting
Study: NCT02268695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT04065971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LHERP®
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT04357665

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral TAPP Repair
Description: laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
Study: NCT02268695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracile

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte colony-stimulating factor (G-CSF)
Study: NCT03080116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509
Description: 240mg/day (4x60mg tablets, Oral administration: OS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: 1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: 1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4 tablets, per OS
Study: NCT04357665

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open PP Repair
Description: Open pre-peritoneal repair using single mesh fixed by sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Lichtenstein Repair
Description: Bilateral Lichtenstein Repair using 2 separate meshes fixed by sutures
Study: NCT04370756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice
Description: Participants randomly assigned to the EX + BR group will consume 140 mL beetroot juice containing approximately 12 mmol of nitrate 3 hours prior to the supervised exercise training component.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Participants will perform 8 weeks of supervised exercise training at a frequency of 3x per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Participants will perform 8 weeks of supervised exercise training at a frequency of 3x per week.
Study: NCT02985983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Administered Brodalumab by subcutaneous (SC) injection until week 66.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Placebo by subcutaneous (SC) injection until week 16. Administered Brodalumab by SC injection from week 17 until week 66.
Study: NCT04370054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Description: Single IV infusion
Study: NCT03260582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LifePod®
Description: The software is a web-based application designed to support persons adhering to lifestyle advice and medication. The patient can log information about lifestyle (i.e. diet, exercise, and smoking), measurements (i.e. weight, pulse and blood pressure), symptoms and medication and can review data in graphs displaying registered values in relation to recommended targets. The software provides positive feedback on healthy choices and gives general recommendations on exercise training, physical activity and healthy diet. Reminders are generated in the case of decreasing registrations. Finally, short text messages (SMS) will be sent out 2-3 times a week with tips on healthy lifestyle.
Study: NCT02462525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-838
Description: Varying doses of ABBV-838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-838
Description: Varying doses of ABBV-838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Administered orally per the label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally per the label.
Study: NCT04676451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femto-AK
Description: Astigmatic Keratotomy / Arcuate Incisions for the correction of astigmatism
Study: NCT02043028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest compression with a step stool
Description: Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest compression with a step stool
Description: Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest compression with a kneeling stool
Description: Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest compression with a kneeling stool
Description: Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes
Study: NCT04327141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-IF
Description: Protein pacing and intermittent fasting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HH
Description: Heart Healthy
Study: NCT02269514

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Own Brand Cigarette
Description: combustible cigarette brand style smoked most frequently by subject

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette #1
Description: VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette #2
Description: VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
Study: NCT00794040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add-on citalopram following optimized methylphenidate
Description: After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Add-on placebo following optimized methylphenidate
Description: After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
Study: NCT01154348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-707106
Description: Tablet, taken once daily with morning meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, taken once daily with morning meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, S-707106 plus metformin
Description: Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin, placebo plus metformin
Description: Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily
Study: NCT03359668

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Use of IV contrast during head and neck CT
Description: Use of IV contrast during head and neck CT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Use of IV contrast during head and neck CT
Description: Use of IV contrast during head and neck CT
Study: NCT04097262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own-Price Elasticity
Description: The price of fruit will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-Price Elasticity
Description: The price of fruit will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
Study: NCT03592667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg, one per day before breakfast during 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: One per day before breakfast during 12 weeks.
Study: NCT01098760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment
Description: Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks
Study: NCT02857946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevaglip (linagliptin)
Description: 1 tablet contains 5 mg linagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trajenta (linagliptin)
Description: 1 tablet contains 5 mg linagliptin
Study: NCT03973931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Interventions will include a variety of text messages aimed at improving medication adherence.
Study: NCT02269514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette #3
Description: VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leading U.S. Nicotine Gum
Description: 4 mg nicotine polacrilex gum
Study: NCT03973931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Interventions will include a variety of text messages aimed at improving medication adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Interventions will include a variety of text messages aimed at improving medication adherence.
Study: NCT03181269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention education
Description: An education package that includes an enhanced emphasis on maternal-infant skin-to-skin contact and a detailed activity log for recording early post-partum care practices that includes specific skin-to-skin contact time and frequency goals.
Study: NCT04606537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.
Study: NCT03181269

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Education
Description: An education package that includes a basic emphasis on maternal-infant skin-to-skin contact, as well as other general post-partum care practices and a general early post-partum care practices log without specific skin-to-skin contact goals.
Study: NCT04606537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: 0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: 0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21
Study: NCT03848598

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of local tendon deformation
Description: Ultrasound-based speckle tracking to evaluate the local tendon tissue displacement during isometric exercise.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of local tendon deformation
Description: Ultrasound-based speckle tracking to evaluate the local tendon tissue displacement during isometric exercise.
Study: NCT04182854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemid hydrochlorothiazide
Description: furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;
Study: NCT02603822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12C mannitol
Description: 12C mannitol 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C mannitol
Description: 13C mannitol 100 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: lactulose 1 g
Study: NCT02608697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study: NCT01538901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod 5% cream
Description: 250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
Study: NCT00234221

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strengths Based Case Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Informational Feedback
Study: NCT04581772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Single oral dose
Study: NCT02865499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acarbose
Description: acarbose treatment with meals
Study: NCT04024540

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric dietary restriction
Description: Very low caloric diet
Study: NCT01370681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : HKB0701 and SLM0807, Period II : CJ30001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : CJ30001, Period II : HKB0701 and SLM0807
Study: NCT03757143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine-Alcohol
Description: Povidone-Iodine-Alcohol will be used to disinfect the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine-Alcohol
Description: Povidone-Iodine-Alcohol will be used to disinfect the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-Alcohol
Description: Chlorhexidine-Alcohol will be used to disinfect the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-Alcohol
Description: Chlorhexidine-Alcohol will be used to disinfect the skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insyte Autoguard BC Winged
Description: Pose of Insyte Autoguard BC Winged

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insyte Autoguard BC Winged
Description: Pose of Insyte Autoguard BC Winged

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes
Description: Pose of Nexiva single port catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes
Description: Pose of Nexiva single port catheter
Study: NCT01137552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 780
Description: AMG 780 will be administered by IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 780
Description: AMG 780 will be administered by IV infusion every 2 weeks
Study: NCT04024540

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isocaloric dietary restriction
Description: Very low caloric diet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Laparoscopic vertical sleeve gastrectomy
Study: NCT03123835

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Intervention
Description: After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
Study: NCT03079011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant Injectable Product
Description: 500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)
Study: NCT02262546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole extended-release (ER) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole immediate-release (IR) tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pramipexole Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Placebo
Study: NCT00167830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Biweekly meetings with a behavior specialist to review subject's progress with the protocol and explore challenges subject is facing in adopting healthy lifestyle behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength and Cardiovascular Conditioning
Description: Subjects take part in an exercise program to include 30 minutes of cardiorespiratory exercise at 70% maximum heart rate, and 30 minutes of strength training on Nautilus machines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food selection and portion control
Description: Subjects meet on a biweekly basis with a registered dietitian who presents educational information about healthy food selection and portion control.
Study: NCT00838799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGH-896
Description: 45 mg TID, capsules, 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGH-896
Description: 30 mg TID, capsules, 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGH-896
Description: 15 mg TID, capsules, 14 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: 100 mg, TID, capsules, 14 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: TID, capsules, 14 weeks.
Study: NCT00370721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study: NCT04446897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: autologous mesenchymal stem cells

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment according to clinical protocols
Study: NCT00876655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 di-sodium phosphate salt
Description: One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 free acid phosphate
Description: One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)
Study: NCT03961958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol reduction
Description: Reduction of propofol target concentration